

# National Board of Examinations

Question Paper Name :	DrNB Medical Oncology Paper3
Subject Name :	DrNB Medical Oncology Paper3
Creation Date :	2025-01-19 21:59:47
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

## DrNB Medical Oncology Paper3

Group Number :	1
Group Id :	3271872846
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

## DrNB Medical Oncology Paper3

Section Id :	3271872849
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872853
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718729744 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Paraneoplastic manifestations in small cell lung carcinoma. [5]  
b) Outline management options in small cell lung carcinoma. [5]

**Question Number : 2 Question Id : 32718729745 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Methods of fertility preservation in male patients with cancer. [5]  
b) Indication and impact on survival of risk reduction surgery in female cancer patients. [5]

**Question Number : 3 Question Id : 32718729746 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Adjuvant CDK4/6 inhibitors in early and locally advanced breast cancer. [5]  
b) HER2 low breast cancer. [5]

**Question Number : 4 Question Id : 32718729747 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Immune checkpoint inhibitors in urothelial cancer. [5]  
b) Immunotherapy in Hodgkin's disease. [5]

**Question Number : 5 Question Id : 32718729748 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Lenvatinib. [4]  
b) Mirvetuximab soravtansine. [3]  
c) Dasatinib. [3]

**Question Number : 6 Question Id : 32718729749 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) HPV associated head and neck squamous cell carcinoma (HNSCC ). [5]
- b) Premalignant conditions in HNSCC and their management. [5]

**Question Number : 7 Question Id : 32718729750 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Management of glioblastoma multiforme. [5]
- b) Management of primary CNS lymphoma in the elderly. [5]

**Question Number : 8 Question Id : 32718729751 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Management of high risk GTN. [5]
- b) Prognostic score in GTN. [5]

**Question Number : 9 Question Id : 32718729752 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Management of early stage cervical cancer. [5]
- b) Cervical cancer vaccine. [5]

**Question Number : 10 Question Id : 32718729753 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

- a) Role of MSI in carcinoma colon. [5]
- b) Management of metastatic RCC. [5]